FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy
Authors:
- 1 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 102 (11) , 2589-2600
Abstract
The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is crucial for prognostication and treatment decisions. Due to the limitations of biopsy, noninvasive alternatives including FibroTest and FibroScan have been developed. Our objective was to systematically review studies describing the accuracy of these tests for predicting HCV-related fibrosis. Studies comparing FibroTest or FibroScan versus biopsy in HCV patients were identified via an electronic search. Random effects meta-analyses and areas under summary receiver operating characteristics curves (AUC) were examined to characterize test accuracy for significant fibrosis (F2-4) and cirrhosis. Heterogeneity was explored using meta-regression. Twelve studies were identified, 9 for FibroTest (N = 1,679) and 4 for FibroScan (N = 546). In heterogeneous analyses for significant fibrosis, the AUCs for FibroTest and FibroScan were 0.81 (95% CI 0.78–84) and 0.83 (0.03–1.00), respectively. At a threshold of ∼ 0.60, the sensitivity and specificity of the FibroTest were 47% (35–59%) and 90% (87–92%). For FibroScan (threshold ∼ 8 kPa), corresponding values were 64% (50–76%) and 87% (80–91%), respectively. Methodological quality, the length of liver biopsy specimens, and inclusion of special populations did not explain the observed heterogeneity. However, the diagnostic accuracy of both measures was associated with the prevalence of significant fibrosis and cirrhosis in the study populations. For cirrhosis, the summary AUCs for FibroTest and FibroScan were 0.90 (95% CI not calculable) and 0.95 (0.87–0.99), respectively. FibroTest and FibroScan have excellent utility for the identification of HCV-related cirrhosis, but lesser accuracy for earlier stages. Refinements are necessary before these tests can replace liver biopsy.Keywords
This publication has 74 references indexed in Scilit:
- The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002Annals of Internal Medicine, 2006
- Reversal of Hepatic Fibrosis — Fact or Fantasy?Hepatology, 2006
- Natural History of Hepatitis CClinics in Liver Disease, 2005
- Current and Future Concepts in Hepatitis C TherapySeminars in Liver Disease, 2005
- Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis CComparative Hepatology, 2004
- Controversies in liver biopsy: Who, where, when, how, why?Current Gastroenterology Reports, 2004
- Transient elastography: a new noninvasive method for assessment of hepatic fibrosisUltrasound in Medicine & Biology, 2003
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis CHepatology, 2003
- Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patientsAIDS, 2003
- Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective studyThe Lancet, 2001